IL115420A0
(en)
|
1994-09-26 |
1995-12-31 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
GB9516709D0
(en)
*
|
1995-08-15 |
1995-10-18 |
Zeneca Ltd |
Medicament
|
US6313127B1
(en)
|
1996-02-02 |
2001-11-06 |
Zeneca Limited |
Heterocyclic compounds useful as pharmaceutical agents
|
GB9602166D0
(en)
*
|
1996-02-02 |
1996-04-03 |
Zeneca Ltd |
Aminoheterocyclic derivatives
|
BR9711135A
(pt)
*
|
1996-08-14 |
1999-08-17 |
Zeneca Ltd |
Composto composi-Æo farmac-utica utiliza-Æo de um composto e processos para prepara-Æo de um composto e para inibi-Æo de Äxido-equaleno ciclase num animal de sangue quente requerendo um tal tratamento
|
UA56197C2
(uk)
*
|
1996-11-08 |
2003-05-15 |
Зенека Лімітед |
Гетероциклічні похідні
|
US6440972B1
(en)
|
1997-02-13 |
2002-08-27 |
Zeneca Limited |
Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
|
GB9801231D0
(en)
|
1997-06-05 |
1998-03-18 |
Merck & Co Inc |
A method of treating cancer
|
KR100375421B1
(ko)
*
|
1997-07-15 |
2003-05-12 |
주식회사 엘지생명과학 |
항암효과를갖는파네실전이효소저해제
|
GB9715895D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
US6387903B1
(en)
|
1997-08-27 |
2002-05-14 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6160118A
(en)
*
|
1998-07-01 |
2000-12-12 |
Merck & Co., Inc. |
Process for the synthesis of substituted piperazinones via Mitsunobu reaction
|
WO2000001674A1
(en)
*
|
1998-07-01 |
2000-01-13 |
Merck & Co., Inc. |
Process for making 1,5-disubstituted imidazoles
|
AU4844599A
(en)
*
|
1998-07-01 |
2000-01-24 |
Merck & Co., Inc. |
Process for the synthesis of substituted piperazinones via mitsunobu reaction
|
EP1090012A4
(en)
|
1998-07-02 |
2005-04-06 |
Merck & Co Inc |
INHIBITORS OF PRENYL PROTEIN TRANSFERASE
|
HRP990246A2
(en)
*
|
1998-08-07 |
2000-06-30 |
Du Pont Pharm Co |
Succinoylamino benzodiazepines as inhibitors of a beta protein production
|
NZ525513A
(en)
|
1998-08-07 |
2004-09-24 |
Pont Pharmaceuticals Du |
Succinoylamino lactams as inhibitors of Abeta protein production
|
IL142816A0
(en)
*
|
1998-12-24 |
2002-03-10 |
Du Pont Pharm Co |
SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
|
GB9902989D0
(en)
|
1999-02-11 |
1999-03-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
CA2362493A1
(en)
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
CA2363169A1
(en)
|
1999-03-03 |
2000-09-08 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
JP2002538121A
(ja)
*
|
1999-03-03 |
2002-11-12 |
メルク エンド カムパニー インコーポレーテッド |
プレニルタンパク質トランスフェラーゼの阻害剤
|
JP2002538120A
(ja)
|
1999-03-03 |
2002-11-12 |
メルク エンド カムパニー インコーポレーテッド |
プレニルタンパク質トランスフェラーゼの阻害剤
|
JP2002542155A
(ja)
|
1999-03-03 |
2002-12-10 |
メルク エンド カムパニー インコーポレーテッド |
プレニル蛋白トランスフェラーゼの阻害剤
|
AU4063600A
(en)
*
|
1999-04-05 |
2000-10-23 |
Merck & Co., Inc. |
A method of treating cancer
|
AU5464200A
(en)
*
|
1999-06-09 |
2000-12-28 |
Merck & Co., Inc. |
Biaryl inhibitors of prenyl-protein transferase
|
US6458935B1
(en)
*
|
1999-06-23 |
2002-10-01 |
Merck & Co., Inc. |
Radiolabeled farnesyl-protein transferase inhibitors
|
WO2001007437A1
(en)
*
|
1999-07-21 |
2001-02-01 |
Merck & Co., Inc. |
Crystal forms of 1-(3-chlorophenyl)-4-[1-(4-cyanobenzyl)-5-imidazolylmethyl]-2-piperazinone
|
US6333335B1
(en)
|
1999-07-23 |
2001-12-25 |
Merck & Co., Inc. |
Phenyl-protein transferase inhibitors
|
CA2384151A1
(en)
|
1999-09-09 |
2001-03-15 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6503902B2
(en)
|
1999-09-13 |
2003-01-07 |
Bristol-Myers Squibb Pharma Company |
Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
|
US6960576B2
(en)
|
1999-09-13 |
2005-11-01 |
Bristol-Myers Squibb Pharma Company |
Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
|
EP1222176A1
(en)
|
1999-10-08 |
2002-07-17 |
Bristol-Myers Squibb Pharma Company |
AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
|
AU2001227755A1
(en)
|
2000-01-12 |
2001-07-24 |
Merck And Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6525044B2
(en)
|
2000-02-17 |
2003-02-25 |
Bristol-Myers Squibb Company |
Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production
|
US6495540B2
(en)
|
2000-03-28 |
2002-12-17 |
Bristol - Myers Squibb Pharma Company |
Lactams as inhibitors of A-β protein production
|
CN1436175A
(zh)
*
|
2000-04-03 |
2003-08-13 |
布里斯托尔-迈尔斯斯奎布药品公司 |
作为Aβ-蛋白生产抑制剂的环状内酰胺
|
BR0110051A
(pt)
|
2000-04-03 |
2004-12-07 |
Bristol Myers Squibb Pharma Co |
Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer
|
AU5144201A
(en)
*
|
2000-04-10 |
2001-10-23 |
Merck & Co Inc |
Inhibitors of prenyl-protein transferase
|
AU2001251444A1
(en)
|
2000-04-10 |
2001-10-23 |
Merck And Co., Inc. |
Inhibitors of prenyl-protein transferase
|
US6534506B2
(en)
|
2000-04-10 |
2003-03-18 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
EP1289966A1
(en)
|
2000-04-11 |
2003-03-12 |
Bristol-Myers Squibb Pharma Company |
SUBSTITUTED LACTAMS AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
|
US20100009966A1
(en)
*
|
2001-04-11 |
2010-01-14 |
Bristol-Myers Squibb Pharma Company |
Substituted lactams as inhibitors of abeta protein production
|
AU2001261728A1
(en)
*
|
2000-05-17 |
2001-11-26 |
Bristol-Myers Squibb Pharma Company |
Use of small molecule radioligands for diagnostic imaging
|
GB0012718D0
(en)
*
|
2000-05-24 |
2000-07-19 |
Angeletti P Ist Richerche Bio |
Conjugates of aminodrugs
|
WO2001092235A1
(en)
|
2000-06-01 |
2001-12-06 |
Bristol-Myers Squibb Pharma Company |
LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
|
US20090062256A1
(en)
*
|
2001-06-01 |
2009-03-05 |
Bristol-Myers Squibb Pharma Company |
LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
|
US7732451B2
(en)
*
|
2001-08-10 |
2010-06-08 |
Palatin Technologies, Inc. |
Naphthalene-containing melanocortin receptor-specific small molecule
|
US7718802B2
(en)
|
2001-08-10 |
2010-05-18 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific piperazine compounds
|
US7655658B2
(en)
*
|
2001-08-10 |
2010-02-02 |
Palatin Technologies, Inc. |
Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
|
EP1425029A4
(en)
*
|
2001-08-10 |
2006-06-07 |
Palatin Technologies Inc |
PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
|
US7456184B2
(en)
*
|
2003-05-01 |
2008-11-25 |
Palatin Technologies Inc. |
Melanocortin receptor-specific compounds
|
US7354923B2
(en)
*
|
2001-08-10 |
2008-04-08 |
Palatin Technologies, Inc. |
Piperazine melanocortin-specific compounds
|
US7727990B2
(en)
|
2003-05-01 |
2010-06-01 |
Palatin Technologies, Inc. |
Melanocortin receptor-specific piperazine and keto-piperazine compounds
|
US7968548B2
(en)
|
2003-05-01 |
2011-06-28 |
Palatin Technologies, Inc. |
Melanocortin receptor-specific piperazine compounds with diamine groups
|
US7727991B2
(en)
|
2003-05-01 |
2010-06-01 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific single acyl piperazine compounds
|
KR101157272B1
(ko)
|
2003-07-22 |
2012-06-15 |
아레나 파마슈티칼스, 인크. |
5?ht2a 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체
|
US7176635B2
(en)
*
|
2004-02-24 |
2007-02-13 |
Musco Corporation |
Apparatus and method for compensating for reduced light output of a light source having a lumen depreciation characteristic over its operational life
|
WO2005089518A2
(en)
*
|
2004-03-18 |
2005-09-29 |
The Brigham And Women's Hospital, Inc. |
Uch-l1 expression and cancer therapy
|
CA2559221A1
(en)
*
|
2004-03-18 |
2005-09-29 |
Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
US20050272722A1
(en)
*
|
2004-03-18 |
2005-12-08 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies
|
EP1732549A4
(en)
*
|
2004-03-18 |
2009-11-11 |
Brigham & Womens Hospital |
METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
|
US20050277629A1
(en)
*
|
2004-03-18 |
2005-12-15 |
The Brigham And Women's Hospital, Inc. |
Methods for the treatment of synucleinopathies (Lansbury)
|
US20070293539A1
(en)
*
|
2004-03-18 |
2007-12-20 |
Lansbury Peter T |
Methods for the treatment of synucleinopathies
|
US7709484B1
(en)
|
2004-04-19 |
2010-05-04 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific piperazine compounds
|
KR101155335B1
(ko)
*
|
2005-01-07 |
2012-06-11 |
엘지전자 주식회사 |
이동통신 단말기의 멀티미디어 메시지 동작방법
|
US20060194821A1
(en)
*
|
2005-02-18 |
2006-08-31 |
The Brigham And Women's Hospital, Inc. |
Compounds inhibiting the aggregation of superoxide dismutase-1
|
LT2474545T
(lt)
|
2005-12-13 |
2017-02-27 |
Incyte Holdings Corporation |
Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
|
US7834017B2
(en)
|
2006-08-11 |
2010-11-16 |
Palatin Technologies, Inc. |
Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
|
TWI415845B
(zh)
|
2006-10-03 |
2013-11-21 |
Arena Pharm Inc |
用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
|
LT3070090T
(lt)
|
2007-06-13 |
2019-06-25 |
Incyte Holdings Corporation |
Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
|
US9567327B2
(en)
|
2007-08-15 |
2017-02-14 |
Arena Pharmaceuticals, Inc. |
Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
|
US7767826B2
(en)
*
|
2007-10-05 |
2010-08-03 |
Pharmatech International, Inc. |
Process for the synthesis of L-(+)-ergothioneine
|
AU2008350907A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
US7932036B1
(en)
|
2008-03-12 |
2011-04-26 |
Veridex, Llc |
Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
|
US8232402B2
(en)
*
|
2008-03-12 |
2012-07-31 |
Link Medicine Corporation |
Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
|
US20110021538A1
(en)
|
2008-04-02 |
2011-01-27 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
CN104784173B
(zh)
|
2008-10-28 |
2019-07-26 |
艾尼纳制药公司 |
用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
|
US9126946B2
(en)
|
2008-10-28 |
2015-09-08 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
|
US20110060005A1
(en)
*
|
2008-11-13 |
2011-03-10 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
US20100331363A1
(en)
*
|
2008-11-13 |
2010-12-30 |
Link Medicine Corporation |
Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
|
WO2010057006A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Link Medicine Corporation |
Azaquinolinone derivatives and uses thereof
|
US8247990B1
(en)
|
2008-12-05 |
2012-08-21 |
Musco Corporation |
Apparatus, method, and system for improved switching methods for power adjustments in light sources
|
MY161416A
(en)
|
2009-05-22 |
2017-04-14 |
Incyte Holdings Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
|
JP5775070B2
(ja)
*
|
2009-05-22 |
2015-09-09 |
インサイト・コーポレイションIncyte Corporation |
ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体
|
US9249145B2
(en)
*
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
AR081315A1
(es)
*
|
2010-03-10 |
2012-08-08 |
Incyte Corp |
Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
|
ME02445B
(me)
|
2010-05-21 |
2016-09-20 |
Incyte Holdings Corp |
Topikalna formulacija za inhibiciju jak-a
|
WO2011153359A1
(en)
|
2010-06-04 |
2011-12-08 |
Albany Molecular Research, Inc. |
Glycine transporter-1 inhibitors, methods of making them, and uses thereof
|
CN103328971B
(zh)
|
2010-07-28 |
2016-09-28 |
维里德克斯有限责任公司 |
急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
AR083933A1
(es)
|
2010-11-19 |
2013-04-10 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
PE20140832A1
(es)
|
2011-06-20 |
2014-07-14 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
CA3178452A1
(en)
|
2012-11-15 |
2014-05-22 |
Incyte Holdings Corporation |
Sustained-release dosage forms of ruxolitinib
|
LT3489239T
(lt)
|
2013-03-06 |
2022-03-10 |
Incyte Holdings Corporation |
Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai
|
ME03564B
(me)
|
2013-03-13 |
2020-07-20 |
Forma Therapeutics Inc |
DERIVATI 2-HIDROKSI-1-{4-[(4-FENILFENIL)KARBONIL]PIPERAZIN-1-IL}ETAN-1-ONA l SRODNA JEDINJENJA KAO INHIBITORI SINTAZE MASNIH KISELINA (FASN) ZA LEČENJE KANCERA
|
MY195091A
(en)
|
2013-08-07 |
2023-01-10 |
Incyte Corp |
Sustained Release Dosage Forms for a JAK1 Inhibitor
|
WO2015070367A1
(en)
*
|
2013-11-12 |
2015-05-21 |
Merck Sharp & Dohme Corp. |
Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
KR102026342B1
(ko)
|
2014-10-24 |
2019-09-27 |
란도스 바이오파마, 인크. |
란티오닌 합성효소 c-유사 2-계 치료제
|
EP4119141A1
(en)
|
2015-06-12 |
2023-01-18 |
Axovant Sciences GmbH |
Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder
|
JP2018520187A
(ja)
|
2015-07-15 |
2018-07-26 |
アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH |
神経変性疾患と関連する幻覚の予防および処置のために有用な5−ht2aセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
|
PT3385395T
(pt)
|
2015-08-17 |
2020-05-06 |
Kura Oncology Inc |
Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
|
MX2019005065A
(es)
|
2016-11-03 |
2019-08-21 |
Kura Oncology Inc |
Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.
|
EP4092013A1
(en)
|
2017-06-20 |
2022-11-23 |
Imbria Pharmaceuticals, Inc. |
Compositions and methods for increasing efficiency of cardiac metabolism
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
WO2019152374A1
(en)
|
2018-01-30 |
2019-08-08 |
Incyte Corporation |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
MX2020010322A
(es)
|
2018-03-30 |
2022-11-30 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
CN113382633A
(zh)
|
2018-10-29 |
2021-09-10 |
福马治疗股份有限公司 |
(4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
|
WO2020190604A1
(en)
|
2019-03-15 |
2020-09-24 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
BR112022002387A2
(pt)
|
2019-12-20 |
2022-09-06 |
Landos Biopharma Inc |
Composto da fórmula z-y-q-y' ou um sal ou éster farmaceuticamente aceitável do mesmo
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|